Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Adaptimmune Therapeutics (ADAP)
NASDAQ:ADAP
RESEARCH TOOLSreports
Holding ADAP?
Track your performance easily
ADAP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.42 - $2.05
Previous Close$0.8
Volume687.53K
Average Volume (3M)1.19M
Market Cap
$198.66M
Enterprise Value$31.21M
Total Cash (Recent Filing)$214.79M
Total Debt (Recent Filing)$47.35M
Price to Earnings (P/E)―
Beta2.85
Next Earnings
Nov 13, 2024EPS Estimate
>-$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding255,740,000
10 Day Avg. Volume1,107,019
30 Day Avg. Volume1,192,931
Standard Deviation0.48
R-Squared0.06
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.10
Price to Sales (P/S)1.40
Price to Cash Flow (P/CF)1.10
P/FCF Ratio1.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.22
Enterprise Value/Gross Profit0.52
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$2.43Price Target Upside204.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Adaptimmune Therapeutics News
PremiumCompany Announcements
Adaptimmune’s TECELRA®: FDA Approval Marks Solid Tumor Breakthrough
Bulls Say, Bears Say
Bulls Say
Commercial ExpansionManagement expects the number of ATCs to grow from the initial 6-10 to approximately 30 within two years of launch.
FDA ApprovalADAP recently received FDA accelerated approval for Tecelra, marking the first approval of a cell therapy to treat solid tumors.
Financial PerformanceEarnings per share was $0.27 vs. consensus of ($0.04).
Bears Say
Commercial ExecutionChallenges in commercial execution and limited revenue opportunities may hinder the company's growth prospects.
Guidance StrategyThe company's decision to move away from formal cash runway guidance could indicate uncertainty in financial planning.
Stock PerformanceShares have decreased by 23% since the approval of Tecelra, reflecting potential investor concerns.
---
Ownership Overview
48.57% Insiders
0.10% Mutual Funds
6.74% Other Institutional Investors
44.35% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ADAP FAQ
What was Adaptimmune Therapeutics’s price range in the past 12 months?
Adaptimmune Therapeutics lowest stock price was $0.42 and its highest was $2.05 in the past 12 months.
What is Adaptimmune Therapeutics’s market cap?
Currently, no data Available
When is Adaptimmune Therapeutics’s upcoming earnings report date?
Adaptimmune Therapeutics’s upcoming earnings report date is Nov 13, 2024 which is in 4 days.
How were Adaptimmune Therapeutics’s earnings last quarter?
Adaptimmune Therapeutics released its earnings results on Aug 12, 2024. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.044 by $0.084.
Is Adaptimmune Therapeutics overvalued?
According to Wall Street analysts Adaptimmune Therapeutics’s price is currently Undervalued.
Does Adaptimmune Therapeutics pay dividends?
Adaptimmune Therapeutics does not currently pay dividends.
What is Adaptimmune Therapeutics’s EPS estimate?
Adaptimmune Therapeutics’s EPS estimate is >-$0.01.
How many shares outstanding does Adaptimmune Therapeutics have?
Adaptimmune Therapeutics has 255,745,440 shares outstanding.
What happened to Adaptimmune Therapeutics’s price movement after its last earnings report?
Adaptimmune Therapeutics reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.044. Following the earnings report the stock price went up 10.101%.
Which hedge fund is a major shareholder of Adaptimmune Therapeutics?
Among the largest hedge funds holding Adaptimmune Therapeutics’s share is Matrix Capital Management Company, LP. It holds Adaptimmune Therapeutics’s shares valued at 38M.
---
Adaptimmune Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.43 (204.93% Upside)
$2.43 (204.93% Upside)
Blogger Sentiment
Bullish
ADAP Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 8.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.5%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
41.63%
12-Months-Change
Fundamentals
Return on Equity
-65.09%
Trailing 12-Months
Asset Growth
-6.20%
Trailing 12-Months
Company Description
Adaptimmune Therapeutics
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
---
ADAP Earnings Call
Q2 2024
0:00 / 0:00
---
ADAP Stock 12 Month Forecast
Average Price Target
$2.43
▲(204.93% Upside)
Technical Analysis
Best Analysts Covering ADAP
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+14.75%
assigned a sell rating 3 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +14.75% per trade.
---